News

After 66 weeks of treatment, patients on eplontersen showed sustained reduction in TTR concentration, halted progression of neuropathy impairment, and improved quality of life.

The associate professor of neurology at the Cleveland Clinic Lerner College of Medicine of Case Western University discussed a presentation at AAN 2023 characterizing the clinical and MRI features of Latinx with multiple sclerosis. [WATCH TIME: 4 minutes]

In comparison with placebo, atogepant 30 mg twice daily and 60 mg once daily resulted in greater reductions in monthly migraine days, as well as proportion of patients with at least 50% reduction in 3-month average of MMDs.

The chief medical officer and cofounder of CND Life Sciences, who served as principal investigator of the study, offered insight into the Syn-ONe Test's clinical utility.

The pump, attached to a wearable retainer, continuously delivers the liquid medication with little to no adverse effects.

The treatment was superior in preventing on-trial relapse in both the monotherapy and immunosuppressive therapy groups compared with placebo in the CHAMPION-NMOSD trial.

The professor of neurology at King’s College, London, spoke about the phase 3 ELEVATE trial investigating atogepant for episodic migraine at the 2023 AAN Annual Meeting. [WATCH TIME: 5 minutes]

The head of the Stroke Program and Medical Director of the Comprehensive Stroke Center at Cleveland Clinic provided perspective on the ENRICH trial, the first positive surgical trial for intracerebral hemorrhage. [WATCH TIME: 5 minutes]

CND Life Sciences’ α-synuclein skin biopsy test showed sensitivity rates ranging from 92.7% to 100% across a number of assessed and clinically confirmed synucleinopathies, including Parkinson disease and dementia with Lewy bodies, among others.

A greater proportion of patients on ubrogepant reported absence of moderate-to-severe intensity headache within 48 hours, ability to function normally, and absence of headache of any intensity.

Giants of Multiple Sclerosis is a premier neuroscience award that celebrates pioneers, innovators, and difference makers who have been selected by their peers for their remarkable achievements in multiple sclerosis.

The director of Cleveland Clinic’s Epilepsy Center provided an update on the World Brain Study, a large-scale, longitudinal study aimed to observe the early, underlying changes in neurological disorders. [WATCH TIME: 9 minutes]

The president elect of the Association of University Professors of Neurology provided thoughts on the promising concepts in neurology and the reasons young medical professionals should join the field.

In single-ascending dose and multiple-ascending dose studies, no clinically meaningful changes were noted in hematology, chemistry, vital signs, or electrocardiogram parameters.

Neurona Therapeutics’ single-administration allogeneic cell therapy suggests thus far that the treatment is safe, with signs of efficacy, after reading out data from the first 2 patients dosed.

The behavioral neurologist at VA Boston Healthcare System talked about screening patients for mild cognitive impairment to improve diagnosis in Alzheimer disease at the 2023 AAN Annual Meeting. [WATCH TIME: 5 minutes]

After 192 weeks, more than 90% of patients on ocrelizumab had no relapses and slightly more than 80% had no 24-week confirmed disability progression.

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Angela Genge, MD, FRCPC. [LISTEN TIME: 13 minutes]

Branded as Qalsody, the FDA has granted approval to Biogen and Ionis' tofersen, making it the fourth therapy approved for ALS and the first for SOD1-associated disease.

The director of the Massachusetts General Hospital ALS Care Center talked about CNM-Au8 treatment across three populations, as well as the HEALEY ALS Platform Trial, at the 2023 AAN annual meeting. [WATCH TIME: 5 minutes]

Higher rates of no evidence of disease activity and no 24-week confirmed disability progression or relapses were observed in patients that continued with ocrelizumab.

The manager of Clinical Development-Research at Linus Health provided perspective on 2 analyses presented at the 2023 AAN Annual Meeting on the reliability of the DCTclock to detect cognitive impairment. [WATCH TIME: 4 minutes]

No significant differences between P2B001 and Prami-ER were seen in total UPDRS responders, UPDRS Part II, and UPDRS Part III scores among those with Parkinson disease.

The senior investigator at the National Institute on Aging talked about targeting pathologies in neurodegenerative diseases at the 2023 AAN Annual Meeting. [WATCH TIME: 6 minutes]

Adverse events like dyskinesia, ON and OFF phenomenon, and falls, were all higher during the 4-week optimization phase than the 8-week maintenance phase.

Compared with immediate-release levodopa/carbidopa, NeuroDerm’s 24-hour subcutaneous liquid infusion improved ON time without dyskinesia and with nontroublesome dyskinesia.

Findings showed a significant reduction in mean monthly migraine days with atogepant 60 mg once daily for patients with episodic migraine compared with placebo across a 12-week period.

In a subgroup of patients with 300 m to 400 m 6MWD scores in the phase 3 Study 041, ataluren (Translarna; PTC Therapeutics) showed particular improvements from baseline.

The pediatric neuroimmunology fellow at NYU Langone provided perspective on a study presented at AAN 2023 comparing cognitive trajectories of pediatric and adult multiple sclerosis. [WATCH TIME: 3 minutes]

Zavegepant, a calcitonin gene-related peptide (CGRP) receptor antagonist, provided onset of pain relief as early as 15 minutes postdose and sustained benefits to 48 hours post dose.